Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a strong sell rating in a research report released on Saturday morning.

Separately, Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Keros Therapeutics presently has an average rating of “Hold” and an average target price of $20.40.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $10.50 on Friday. Keros Therapeutics has a 1 year low of $10.30 and a 1 year high of $22.55. The firm has a fifty day moving average price of $11.44 and a 200-day moving average price of $15.71. The company has a market cap of $207.80 million, a price-to-earnings ratio of -3.49 and a beta of 0.95.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The firm had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a negative return on equity of 14.91% and a negative net margin of 256.60%. Equities research analysts expect that Keros Therapeutics will post -4.93 EPS for the current year.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Financial Management Professionals Inc. purchased a new position in shares of Keros Therapeutics during the fourth quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd increased its position in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares during the period. SG Americas Securities LLC purchased a new position in shares of Keros Therapeutics during the third quarter worth approximately $103,000. Finally, CWM LLC increased its position in shares of Keros Therapeutics by 45.4% during the third quarter. CWM LLC now owns 7,271 shares of the company’s stock worth $115,000 after acquiring an additional 2,271 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.